Banks play a critical role in the financial system, providing everything from commercial loans to wealth management and ...

Amid the threat of pharmaceutical tariffs from President Donald Trump, recent months have seen multibillion-dollar U.S.

The bond will count as Tier-II capital, according to a decision made at the bank’s board meeting on 19 June, which was disclosed through a price-sensitive information notice in newspapers and on its w ...

UCB, a global biopharmaceutical company focused on improving the lives of people with severe diseases, today announced plans for a significant investment in a new, state-of-the-art biologics ...

Belgium’s largest drugmaker UCB has announced plans for a significant investment in a new, state-of-the-art biologics ...

On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating dapirolizumab ...

We recently wrote an introductory overview of navigating the Common Law Research Exemption and the Hatch-Waxman Safe Harbor ...

Sarah Priestley, project manager for International Partnerships at the University of Central Lancashire (UCLan), spoke with Md Belal Hossen of The Business Standard about how British degrees offered ...

UCB has three products currently in phase III which are due to produce pivotal results in the next few years: brivaracetam for epilepsy, lupus treatment epratuzumab and romosozumab for osteoporosis.

Belgian pharmaceutical company UCB says it plans to invest $5bn in a US factory to avoid President Trump’s tariffs on the EU.

A Belgian pharmaceutical company with its American base in Atlanta is teasing a transformative factory for biologics in the United States.  It’s yet unclear, however, how much of its suggested $5 ...